Dr Fraikin developed Spectradyne’s initial Microfluidic Resistive Pulse Sensing technology as part of his PhD thesis work at UC Santa Barbara in the research group of Dr. Andrew Cleland. After graduating he received postdoctoral training in cancer cell biology and biochemistry and worked in industry developing microfluidics-based molecular diagnostics. Dr. Fraikin is a co-founder of Spectradyne and now serves as the company’s CEO.
Trends in EV Characterization Technologies
Tuesday, 1 March 2022 at 16:00
Add to Calendar ▼2022-03-01 16:00:002022-03-01 17:00:00Europe/LondonTrends in EV Characterization TechnologiesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Methods for characterizing EVs are evolving, and new technologies are being developed that deliver size, concentration, and fluorescent phenotyping, each to a varying degree of success. Learn about how some of these new and cutting-edge technologies work, their strengths and weaknesses, and where we at Spectradyne see the technology landscape moving next.
Add to Calendar ▼2022-03-01 00:00:002022-03-02 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-03-01 16:00:002022-03-01 17:00:00Europe/LondonTrends in EV Characterization TechnologiesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
